Answers are grounded in this paper and cite their sources.
To the Editors: Winkler et al. (2008) give an excellent description of the "head nodding syndrome," a disorder that has been found linked with epileptic seizures in four distinct geographic locations of sub-Saharan Africa (Jilek-Aall et al., 1979; Van der Waals et al., 1983; Kaiser et al., 2000; Lacey, 2003), all of which known as endemic for Onchocerca volvulus, the causative agent of river blindness. Over the last decade, O. volvulus has increasingly been implicated in the observation of clustering excess prevalence of epilepsy (Pion et al., 2009). With this background, the study of Winkler et al. is of great interest because, for the first time, it provides results of magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analysis of patients with epilepsy living in an onchocerciasis endemic area. A search for a pathologic substrate inducing epilepsy by O. volvulus should aim at the demonstration of the parasite in the central nervous system (CNS). Certainly, the macrofilarial stages of the parasite, because of their size (length 5–50 cm; width 0.1–0.45 mm), would be expected to produce clearly visible lesions and the absence of such findings argues against the involvement of the adult stage of O. volvulus in the CNS. However, the pattern of the pathologic MRI findings still leaves room for speculation about microfilariae (length 220–300 μm) producing more subtle changes in the brain. Even if no microfilariae are found in the CSF, one may consider changes due to degrading microfilariae, or to persisting immune reactions to these. Winkler et al. do not provide information on antifilarial medication prior to their patients' enrollment in the study, although this may have significantly influenced the results of their parasitologic examinations. Throughout most of the African endemic areas, patients with onchocerciasis are treated with the microfilaricidal drug ivermectin (Mectizan), which has been made available at no cost by its manufacturer (Merck & Co., Whitehouse Station, NJ, U.S.A.) since 1987. In Mahenge, the study area of Winkler et al., annual mass treatment has been carried out since 1998, with therapeutic coverage reaching up to 70% (WHO/APOC, 2007), and it appears likely that many of their patients already had received ivermectin. The very low microfilarial counts found in dermal biopsies also strongly indicate previous treatment with ivermectin. In view of the potent effect of ivermectin on O. volvulus microfilariae (Basáñez et al., 2008) it cannot be excluded that in the patients with head nodding examined by Winkler et al. microfilariae could have been present in the CSF before treatment, as they were previously demonstrated in the CSF of untreated patients (Duke et al., 1976). Ultimately, the article of Winkler et al. leaves unsolved the question as to whether the phenomenon of head nodding constitutes a feature of an epileptic syndrome caused by O. volvulus. Future investigations should aim at studying patients without history of antiparasitic treatment and involve appropriate comparison groups of persons without epilepsy. We hope that this most interesting article will stimulate more researchers with neurologic and parasitologic background to get involved in this neglected subject. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this letter is consistent with those guidelines. None of the authors has any conflict of interest to disclose.
No takes yet. Share an insight, caveat, or question.
Kaiser et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: